Antidepressant switching patterns in the treatment of major depressive disorder: A General Practice Research Database (GPRD) Study

International Journal of Clinical Practice

Volumn 66, Issue 11, 2012, Pages 1079-1087

  Saragoussi, D ^a   Chollet, J ^a   Bineau, S ^a   Chalem, Y ^a   Milea, D ^a  

^a Lundbeck   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; HYPNOTIC AGENT; NEUROLEPTIC AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DEPRESSION; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; UNITED KINGDOM;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG SUBSTITUTION; FEMALE; GENERAL PRACTICE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867515586     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2012.03015.x     Document Type: Article

References (40)

1. Alonso J, Angermeyer MC, Bernert S, et al., Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004; 420: 21-7.
2. Middleton N, Gunnell D, Whitley E, et al., Secular trends in antidepressant prescribing in the UK, 1975-1998. J Public Health Med 2001; 23: 262-7. (Pubitemid 34087287)
3. Lawrenson RA, Tyrer F, Newson RB, Farmer RD,. The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 2000; 59: 149-57. (Pubitemid 30317431)
4. Dunn RL, Donoghue JM, Ozminkowski RJ, et al., Longitudinal patterns of antidepressant prescribing in primary care in the UK: comparison with treatment guidelines. J Psychopharmacol 1999; 13: 136-43. (Pubitemid 29276823)
5. Kendrick T, King F, Albertella L, Smith PW,. GP treatment decisions for patients with depression: an observational study. Br J Gen Pract 2005; 55: 280-6. (Pubitemid 40520904)
6. Meijer WE, Heerdink ER, Pepplinkhuizen LP, et al., Prescribing patterns in patients using new antidepressants. Br J Clin Pharmacol 2001; 51: 181-3. (Pubitemid 32216070)
7. Percudani M, Barbui C, Fortino I, Petrovich L,. Antidepressant drug use in Lombardy, Italy: a population-based study. J Affect Disord 2004; 83: 169-75. (Pubitemid 39536191)
8. Pietraru C, Barbui C, Poggio L, Tognoni G,. Antidepressant drug prescribing in Italy, 2000: analysis of a general practice database. Eur J Clin Pharmacol 2001; 57: 605-9.
9. Rosholm JU, Andersen M, Gram LF,. Are there differences in the use of selective serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database study Eur J Clin Pharmacol 2001; 56: 923-9. (Pubitemid 33788571)
10. American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000; 157: 1-45.
11. Agency for Health Care Policy and Research. Treatment of major depression: clinical practice guideline. 1993.
12. NICE (National Institute for Health and Clinical Excellence). Depression: management of depression in primary and secondary care. National Clinical Practice Guideline Number 23 (amended). 2007.
13. Schulberg HC, Katon W, Simon GE, Rush AJ,. Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. Arch Gen Psychiatry 1998; 55: 1121-7. (Pubitemid 28558285)
14. Donoghue J,. Antidepressant use patterns in clinical practices: comparisons among tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000; 403: 57-61.
15. Katon W, von Korff M, Lin E, et al., Adequacy and duration of antidepressant treatment in primary care. Med Care 1992; 30: 67-76.
16. Linden M, Gothe H, Dittmann RW, Schaaf B,. Early termination of antidepressant drug treatment. J Clin Psychopharmacol 2000; 20: 523-30.
17. Fava M,. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry 2000; 61 (Suppl. 2): 10-2. (Pubitemid 30131897)
18. McIntyre RS, Muller A, Mancini DA, Silver ES,. What to do if an initial antidepressant fails? Can Fam Physician 2003; 49: 449-57. (Pubitemid 36700651)
19. Marangell LB,. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry 2001; 62 (Suppl. 18): 12-7. (Pubitemid 33736200)
20. Aikens JE, Kroenke K, Swindle RW, Eckert GJ,. Nine-month predictors and outcomes of SSRI antidepressant continuation in primary care. Gen Hosp Psychiatry 2005; 27: 229-36. (Pubitemid 40898247)
21. Bakish D,. How does one switch from one antidepressant to another when there has been a treatment failure? J Psychiatry Neurosci 1998; 23: 264.
22. Bull SA, Hu XH, Hunkeler EM, et al., Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002; 288: 1403-9. (Pubitemid 35025915)
23. Posternak MA, Zimmerman M,. Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment-resistant patients. J Clin Psychiatry 2001; 62: 135-42; quiz 43. (Pubitemid 32199876)
24. Wood L, Martinez C,. The general practice research database: role in pharmacovigilance. Drug Saf 2004; 27: 871-81. (Pubitemid 39331685)
25. Garcia Rodriguez LA, Perez Gutthann S,. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419-25. (Pubitemid 28227341)
26. Jick H, Jick SS, Derby LE,. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 766-8.
27. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al., Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-9. (Pubitemid 36539051)
28. Martinez C, Rietbrock S, Wise L, et al., Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005; 330: 389.
29. Schultz J, Joish V,. Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder. Psychiatr Serv 2009; 60: 1604-11.
30. Sheffield RE, Lo Sasso AT, Young CH, Way K,. Selective serotonin reuptake inhibitor usage patterns as risk factors for hospitalization. Adm Policy Ment Health 2002; 30: 121-39. (Pubitemid 36378683)
31. Mullins CD, Shaya FT, Meng F, et al., Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 2005; 25: 660-7. (Pubitemid 40604881)
32. Marcus SC, Hassan M, Olfson M,. Antidepressant switching among adherent patients treated for depression. Psychiatr Serv 2009; 60: 617-23.
33. Croghan TW, Lair TJ, Engelhart L, et al., Effect of antidepressant therapy on health care utilization and costs in primary care. Psychiatr Serv 1997; 48: 1420-6. (Pubitemid 27465169)
34. Claxton AJ, Li Z, McKendrick J,. Selective serotonin reuptake inhibitor treatment in the UK: risk of relapse or recurrence of depression. Br J Psychiatry 2000; 177: 163-8. (Pubitemid 30624829)
35. Pathiyal A, Hylan TR, Quik R, Jones JK,. Antidepressant use and resource utilization in the general practitioner setting in The Netherlands. Pharmacoepidemiol Drug Saf 1998; 7: 253-60. (Pubitemid 28396296)
36. Isacsson G, Boethius G, Henriksson S, et al., Selective serotonin reuptake inhibitors have broadened the utilisation of antidepressant treatment in accordance with recommendations. Findings from a Swedish prescription database. J Affect Disord 1999; 53: 15-22. (Pubitemid 29227348)
37. Milea D, Guelfucci F, Bent-Ennakhil N, et al., Antidepressant monotherapy: a claims database analysis of treatment changes and treatment duration. Clin Ther 2010; 32: 2057-72.
38. Robinson RL, Long SR, Chang S, et al., Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims. J Manag Care Pharm 2006; 12: 43-54. (Pubitemid 47407591)
39. Sheehan DV, Keene MS, Eaddy M, et al., Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 2008; 22: 963-73.
40. Lam RW, Kennedy SH, Grigoriadis S, et al., Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009; 117 (Suppl. 1): S26-43.